Jul 25, 2023

Farmak launched 9 new medicines in the first half of 2023

Farmak, one of the leading medicine manufacturers in Ukraine, has launched 9 new products in the first half of 2023. The new medicines are intended for a variety of medical applications, including the symptomatic treatment of allergic rhinoconjunctivitis, fungal infections, Herpes Simplex virus types I and II, the treatment of stroke and glaucoma, as well as the treatment of abdominal pain and intestinal disorders.

The company continues to invest significant resources in the research and development of new medicines, even during a full-scale war. It is planned that during the 2nd half of 2023 the company will launch even more new products on the market. Farmak annually invests about $15 million in the development of medicines. During the war year 2022, these investments amounted to more than $13 million.

“Investing in new medicines is a strategically important direction for us, because they allow the company to expand its product portfolio and provide patients with more choice during treatment. Every new drug we develop has the potential to improve people’s quality of life and health. In addition, we attach great importance to the improvement of production technologies. Thanks to this, our medicines are sold not only in Ukraine, but also far beyond its borders,” says Volodymyr Kostiuk, Executive Director of Farmak.

Currently, the company’s product portfolio contains about 400 types of medicines. Among the main types are endocrinological, gastroenterological, cardiological, neurological, anti-cold and other medicines. The company reinvests up to 90% of its profits in development, and the total investment over the past 20 years is more than $400 million. The production facilities and the laboratory and technical complex of Farmak are internationally certified and meet the requirements of European GMP (Good Manufacturing Practice) standards. This allows the company to export products to more than 50 countries around the world.

Back to the News